GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Suven Life Sciences Ltd (BOM:530239) » Definitions » Price-to-Free-Cash-Flow

Suven Life Sciences (BOM:530239) Price-to-Free-Cash-Flow : N/A (As of May. 31, 2025)


View and export this data going back to 1995. Start your Free Trial

What is Suven Life Sciences Price-to-Free-Cash-Flow?

As of today (2025-05-31), Suven Life Sciences's share price is ₹244.70. Suven Life Sciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 was ₹0.00. Hence, Suven Life Sciences's Price-to-Free-Cash-Flow Ratio for today is N/A.

The historical rank and industry rank for Suven Life Sciences's Price-to-Free-Cash-Flow or its related term are showing as below:

BOM:530239's Price-to-Free-Cash-Flow is not ranked *
in the Drug Manufacturers industry.
Industry Median: 23.55
* Ranked among companies with meaningful Price-to-Free-Cash-Flow only.

Suven Life Sciences's Free Cash Flow per Share for the three months ended in Mar. 2025 was ₹0.00. Its Free Cash Flow per Share for the trailing twelve months (TTM) ended in was ₹0.00.

During the past 3 years, the average Free Cash Flow per Share Growth Rate was 7.10% per year. During the past 5 years, the average Free Cash Flow per Share Growth Rate was 9.00% per year.

During the past 13 years, Suven Life Sciences's highest 3-Year average Free Cash Flow per Share Growth Rate was 310.50% per year. The lowest was -34.40% per year. And the median was 4.85% per year.


Suven Life Sciences Price-to-Free-Cash-Flow Historical Data

The historical data trend for Suven Life Sciences's Price-to-Free-Cash-Flow can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Suven Life Sciences Price-to-Free-Cash-Flow Chart

Suven Life Sciences Annual Data
Trend Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24 Mar25
Price-to-Free-Cash-Flow
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Suven Life Sciences Quarterly Data
Jun20 Sep20 Dec20 Mar21 Jun21 Sep21 Dec21 Mar22 Jun22 Sep22 Dec22 Mar23 Jun23 Sep23 Dec23 Mar24 Jun24 Sep24 Dec24 Mar25
Price-to-Free-Cash-Flow Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Suven Life Sciences's Price-to-Free-Cash-Flow

For the Drug Manufacturers - Specialty & Generic subindustry, Suven Life Sciences's Price-to-Free-Cash-Flow, along with its competitors' market caps and Price-to-Free-Cash-Flow data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Suven Life Sciences's Price-to-Free-Cash-Flow Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Suven Life Sciences's Price-to-Free-Cash-Flow distribution charts can be found below:

* The bar in red indicates where Suven Life Sciences's Price-to-Free-Cash-Flow falls into.


;
;

Suven Life Sciences Price-to-Free-Cash-Flow Calculation

Suven Life Sciences's Price-to-Free-Cash-Flow ratio for today is calculated as

Price-to-Free-Cash-Flow Ratio=Share Price/ Free Cash Flow per Share (TTM)
=244.70/0
=N/A

Suven Life Sciences's Share Price of today is ₹244.70.
Suven Life Sciences's Free Cash Flow per Share for the trailing twelve months (TTM) ended in Mar. 2025 adds up the quarterly data reported by the company within the most recent 12 months, which was ₹0.00.

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

It can also be calculated from the numbers for the whole company:

Price-to-Free-Cash-Flow Ratio=Market Cap/Free Cash Flow

Suven Life Sciences  (BOM:530239) Price-to-Free-Cash-Flow Explanation

Free Cash Flow is considered more important than earnings by value investors. The reason is because, in principle, only the net cash that can be taken from the business belongs to shareholders. This Free Cash Flow can be used to grow the business, reduce debt or return to shareholders in dividends or share buybacks.

In a DCF Calculation Free Cash Flow is used to determine the intrinsic value of companies.


Be Aware

In real business, Free Cash Flow can be affected by the change in accounts receivable, accounts payable, management's decision on expansion, etc. Therefore, investors should look at the Free Cash Flow over the longer term. Long-term average of Free Cash Flow is a more reliable indicator for real free cash flow.


Suven Life Sciences Price-to-Free-Cash-Flow Related Terms

Thank you for viewing the detailed overview of Suven Life Sciences's Price-to-Free-Cash-Flow provided by GuruFocus.com. Please click on the following links to see related term pages.


Suven Life Sciences Business Description

Traded in Other Exchanges
Address
Avenue 7, Road No. 5, Banjara Hills, Number 8-2-334, 6th Floor, SDE Serene Chambers, Hyderabad, TG, IND, 500 034
Suven Life Sciences Ltd is an India-based biopharmaceutical company. The company is focused on the acquisition, development, and commercialization of novel therapeutics for the treatment of neurodegenerative disorders. The company's only segment is providing Research and Development services. The company's geographical segment includes India; the USA; Europe and Others. The company generates maximum revenue from the USA. The company earns revenue from the sale of New Chemical Entity (NCE) based Intermediates for CNS disorders.

Suven Life Sciences Headlines

No Headlines